The design of selective non-substrate-based matrix metalloproteinase inhibitors

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 4, 2000, Pages 353-361

  Montana, John ^a   Baxter, Andrew ^a  

^a UCB PHARMA   (Belgium)

Author keywords

3 D QSAR; Inhibitory profile; Matrix metalloproteinase; SAR by NMR; Sheddases; Structure based drug design; X ray structure

Indexed keywords

ABT 770; CARBOXYLIC ACID MMP INHIBITOR; CGS 27023A; CIPEMASTAT; HYDROXAMIC ACID INHIBITOR; L 758354; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; PRINOMASTAT; REBIMASTAT; RO 130830; STROMELYSIN INHIBITOR; TANOMASTAT; THIADIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG SELECTIVITY; ENZYME INHIBITOR INTERACTION; ENZYME SUBSTRATE; INHIBITION KINETICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0033940184     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Birkedal-Hansen H: Proteolytic remodelling of extracellular matrix. Curr Opin Cell Biol (1995) 7:728-735.
2. Woessner JR Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 5:2145-2154.
3. Murphy G: Matrix metalloproteinases and their inhibitors. Ada Orthop Scant/ Suppl (1995) 266:55-60.
4. Toi M, Ishigaki S, Tominaga T: Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat (1998) 52:113-124.
5. Clark IM, Rowan AD, Cawston TE: Matrix metalloproteinase inhibitors in the treatment of arthritis. Curr Opin Antiinflamm Immunomod Invest Drugs (2000) 2:16-25. An excellent and up-to-date review of the role of MMPs and utility ofMMPIs in the treatment of arthritis.
6. Levy DE, Ezrin AM: Matrix metalloproteinase inhibitor drugs. Emerging Drugs (1997) 2:205-230.
7. McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, Sekul L, Truesdale A, Verghese M, Warner J, Ways JP: Regulation of tumor necrosis factor processing by a metalloproteinase inhibitor. Nature (1994) 370:558-561.
8. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL, Leber TM, Mangan M, Miller K, Nayee P, Owen K, Patel S, Thomas W, Wells G, Wood LM, Wooley K: Processing of tumor necrosis factor-a precursor by metalloproteinases. Nature (1994) 370:555-557.
9. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumor-necrosis factor from cells. Nature (1997) 385:729-733.
10. Moss ML, Jin S-LC, Milla ME, Burkhart W, Carter HL, Chen W- J, Clay WC, Didsbury JR, Hassler D, Huffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, Mageehan G, Mitchell J, Moyer M, Panel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su J-L, Wamer J, Willard D, Becherer JD: Cloning of a disintegrin metalloproteinase that processes precursor tumor necrosis factor-a. Nature (1997) 385:733-736.
11. Black RA, White JM: ADAMs: Focus on the protease domain. Curr Opin Cell Biol (1998) 10:654-659. Excellent review highlighting the role of members of this emerging gene family in health and disease.
12. Nelson FC, Zask A: The therapeutic potential of small molecule TACE inhibitors. Exp Opin Invest Drugs (1999) 8:383-392. The first review in the MMPI area with a focus entirely on TACE.
13. Hooper NM, Karran EH, Turner AJ: Membrane protein secretases. Biochem J(1997) 321:265-279.
14. Gallea-Robache S, Morand V, Millet S, Bruneau JM, Bhatnagar N, Chouaib S, Roman-Roman S: A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors In human monocytic cells. Cytokine (1997) 9:340-346.
15. Lombard MA, Wallace TL, Kubicek MF, Petzold GL, Mitchell MA, Hendges SX, Wilks JW: Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (T1MP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-a receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res (1998) 58:4001-4007.
16. Wojtowicz-Praga S, Toni J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Onco/(1998) 16:2150-2156. Perspective on the issues surrounding the utility of first generation MMPIs in the clinical setting.
17. Bird J: What is the appropriate selectivity for development of MMP inhibitors for therapeutic use? Gordon Research Conference: Matrix Metalloproteinases. New London, NH, USA (1999).
18. Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W: Structure determination and analysis of human nuetrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry (1995) 34:14012-14020.
19. Lorenz H-M: Ro-32-3555 Roche Holding. Curr Opinion Antiinflamm Immunomod Invest Drugs (2000) 2:47-52.
20. Malsher PJ, Borkakoti N, Bottomley KM, Cooper Ml, Eatherton AJ, Kilford IR, Broadhurst MJ, Nixon JS, Brown PA, Lewis EJ, Lawton G, Sutton BM, Ballantyne N, Johnson WH: Design and synthesis of the cartilage protective agent (CPA, Ro-323555). Bioorg Med Chem Lett (1997) 7:2299-2302.
21. Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KM: Ro-32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum (1998) 41:1639-1644.
22. Wood ND, Aiken M, Durston S, Harris S, McClelland GR, Sharp S: Cartilage protective agent (CPA) Ro-32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. Agents Actions Suppl (1997) 49:49-55.
23. EULAR (European League against Rheumatism). Vienna, Austria (1997):48.
24. Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewsler M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, Johnson WH, Nixon JS, Rose F, Sutton B, Wilson K: Ro-32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown In vitro and In vivo. Br J Pharmacol (1997)121:540-546.
25. Baxter AD, Bird J, Bannister R, Bhogal R, Manallack DT, Watson RW, Owen DA, Montana J, Henshilwood J, Jackson RC: D1927 and D2163: Novel mercaptoamide inhibitors of matrix metalloproteinases. In: Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Clendeninn NJ, Appell K (Eds), Humana Press Inc, Totowa, NJ, USA (2000) 8:193-221. A comprehensive overview of the discovery and development of mercaptoamide based MMPIs.
26. Naglich JG, Jure-Kunkel M, Gao J, Smith D, Talbott R, Henderson A, Kukral D, Lewin A, Jeyaseelan R, Cardenas V, Gupta E, Huang M, Bannister R, Trail PA: Activities of a synthetic matrix metalloproteinase inhibitor (MMPI), BMS-275291, in models of angiogenesis and tumor metastasis. 97s/ AACR Annual Meeting. April 1-5, San Francisco, CA, USA. Proc Amer Assoc Cancer Res (2000) 41:3122.
27. Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Shen F, Colletti A, Krieter PA, Hagmann WK: Inhibition of stromelysin-1 by Pl'-blphenylylethyl carboxyalkyl dipeptides. JMed Chem (1997) 40:1026-1040.
28. Morphy JR, Millican TA, Porter JR: Matrix metalloproteinase inhibitors: Current status. CurrMed Chem (1995) 2:743-762.
29. Beckett RP, Davidson AH, Drummond AH, Huxley P, Whittaker M: Recent advances in matrix metalloproteinase inhibitor research. Drug Disc Today (1996) 1:16-26.
30. White AD, Thomas MA, Bocan PA, Boxer PA, Peterson JT, Schrier D: Emerging therapeutic advances for the development of second generation matrix metalloproteinase inhibitors. CurrPharm Design (1997) 3:45-58.
31. Beckett RP, Whittaker M: Matrix metalloproteinase inhibitors 1998. Exp Opin Ther Pat (1998) 8:259-282.
32. Michaelides MR, Curtin ML: Recent advances in matrix metalloproteinase inhibitors research. Curr Pharm Design (1999)5:787-819. The most up-to-date and comprehensive review of activities in the highly competitive arena of MMPIs.
33. MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byme EM, Ganu V, Parker DT: Discovery of CGS-27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem (1997) 40:2525-2532.
34. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K: Broad antitumor and antiangiogenic activities of AG-3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NYAcad Sei (1999) 878:236-270.
35. Pikul S, McDow KL, Dunham NG, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE: Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. JMed Chem (1999) 42:87-94. Excellent structural study of a novel class of MMPIs highlighting the critical nature of certain protein inhibitor interactions allowing a better understanding of new inhibitor templates.
36. Bird J, Bhogal R, Baxter A, Willis R, Owen DA: Activity of matrix metalloproteinase inhibitor (MMPI) in models of inflammation. Inflammation '99. Paris, France (1999).
37. Li Y-C, Zhang X, Melton R, Ganu V, Gonnella NC: Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, non-peptidic inhibitor. Biochemistry (1998)37:14048-14056.
38. Lollini L, Haller J, De Lustro B, Caufield J: RS-130830 inhibits cartilage degradation in vitro and in a rabbit model of osteoarthritis. Inhibition of Matrix Metalloproteinases: Therapeutic Applications. October 21-24, Tampa, FL, USA (1998):20.
39. Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, Campbell JA, Walker KA, Martin R, Van Wart H, Browner MF: Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.
40. Nature Struct Biol (1999) 6:217-221. Important publication highlighting the power of structure-based drug design in refining selectivity within the MMP gene family.
41. Babine RE, Bender SL: Molecular recognition of protein-ligand complexes: Applications to drug design. Chem Rev (1997)97:1359-1472. Excellent overview of the role of structure-based drug design in drug discovery.
42. Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, Bayne EK, Flanagan J, Kawka D, Shen CF, Stevens K, Chen H, Trumbauer M, Visco DM: Susceptibility of stromelysin-1 deficient mice to collagen induced arthritis and cartilage destruction. Arthritis Rheum (1998) 41:110-121. Important publication highlighting the dangers of designing truly selective inhibitors ofMMPs.
43. Sorbera LA, Graul A, Silvestre J, Castaner J: BAY-12-9566. Drugs Future (1999) 24:16-21.
44. Morgan DW, Albert DH, Magoc T, Tapang P, Marcotte P, Elmore l, Glaser K, Pease L, Li J, Leal J, Michaelides M, Curtin M, Holms J, Davidsen SK: ABT-770: A novel, selective gelatinase A inhibitor with antitumor activity in pre-clinfcal models of tumor growth. AACR-NCI-EORTC International Conference. Washington DC, USA (1999):764. Introduction to a novel series ofMMPIs with refined selectivity and excellent activity in animal models of cancer.
45. Jacobsen EJ, Mitchell MA, Hendges SK, Belonga KL, Skaletzky LL, Stelzer LS, Undberg TJ, Fritzen EL, Schostarez HJ, O'Sullivan TJ, Maggiora LL, Stuchly CW, Laborde AL, Kubicek MF, Poorman RA, Beck JM, Miller HR, Petzold GL, Scott PS, Truesdell SE, Wallace TL, Wilks JW, Rsher C, Goodman LV, Kaytes PS, Ledbetter SR, Powers EA, Vogeli G, Mott JE, Trepod CM, Staples DJ, Baldwin ET, Finzel BC: Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors. JMed Chem (1999) 42:1525-1536. Excellent review of SAR in a series of compounds that presents not only a novel zinc binding group but also an unusual mode of binding in the active site ofMMPs.
46. Matter H, Schwab W: Affinity and selectivity of matrix metalloproteinase inhibitors: A chemometrical study from the perspective of ligands and proteins. JMed Chem (1999) 42:4506-4523.
47. Sheppard HG, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinman DH, Carrera GM, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW: Discovery of potent non-peptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc (1997) 119:5818-5827.
48. Olejniczak ET, Hajduck PJ, Marcotte PA, Nettesheim DG, Meadows RP, Edalji R, Holzman TF, Fesik SW: Stromelysin inhibitors designed from weakly bound fragments: Effects of linking and cooperativity. J Am Chem Soc (1997) 119:5828-5832. Two consecutive publications highlighting a novel approach to the design of non-substrate-based MMPIs.
49. Browner MF: Matrix metalloproteinases: Structure-based drug discovery targets. Perspect Drug Disc Des (1994) 2:343-351.
50. Borkakoti N: Structural characteristics of the matrix metalloproteinases. In: Metalloproteinases as Targets for Anti-inflammatory Drugs. Bottomley KM, Bradshaw D, Nixon JS (Eds), Berkhauser Verlag, Basel, Switzerland (1999):1-16.
51. Maskos K, Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestad GA, Reddy P, Wolfson MF, Rauch CT, Castner BJ, Davis R, Clarke HR, Petersen M, Fitzner JN, Cerretti DP, March CJ, Paxton RJ, Black RA, Bode W: Crystal structure of the catalytic domain of human tumor necrosis factor-a-converting enzyme. Proc Natl Acad Sei USA (1998) 95:3408-3412. The first crystal structure of an ADAM gene family member. There will be considerable use of structure-based studies in the design of inhibitors of ADAM and ADAM-TS gene family members.